Related Experiment Video
Updated: Aug 25, 2026
Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers
Published on: March 3, 2023
Topical effectiveness of molgramostim (GM-CSF) in sickle cell leg ulcers
Laure Méry1, Robert Girot, Sélim Aractingi
1Service de Dermatologie, Hôpital Tenon, Paris, France. laurepat@wanadoo.fr
Insights
Topical molgramostim effectively healed most sickle cell disease (SCD) leg ulcers in a small study. This recombinant human granulocyte-macrophage colony-stimulating factor shows promise for managing these difficult wounds.
Area of Science:
- Hematology
- Wound Healing
- Regenerative Medicine
Background:
- Leg ulcers are a severe complication of sickle cell disease (SCD), significantly impacting patient quality of life.
- Current management strategies for SCD leg ulcers yield disappointing results.
- Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) has demonstrated efficacy in healing various chronic wounds.
Purpose of the Study:
- To evaluate the efficacy of topical molgramostim solution in treating leg ulcers associated with sickle cell disease.
- To assess the safety and tolerability of this therapeutic approach.
Main Methods:
- A case series involving 5 patients with sickle cell disease (SCD).
- Patients presented with a total of 14 leg ulcers, with durations ranging from 1 month to 6 years.
- Treatment consisted of the local topical application of molgramostim solution via dripping.
Main Results:
- Complete healing was achieved in 9 out of 14 treated leg ulcers.
- No local adverse reactions were reported at the application sites.
- No systemic adverse events were observed during the treatment period.
Conclusions:
- Topical molgramostim solution demonstrates potential as an adequate therapy for sickle cell disease leg ulcers.
- Further investigation with larger patient cohorts is warranted for a more conclusive evaluation.
- Future research may explore alternative formulations for topical GM-CSF to enhance therapeutic effectiveness.
Background:
Leg ulcers are a frequently neglected, severe complication of sickle cell disease (SCD), responsible for significant altering quality of life. The management of leg ulcers remains disappointing. Local application of recombinant human granulocyte-macrophage colony-stimulating factor has been shown to be effective in several types of chronic wound healing.
Methods:
We report 5 homozygous sickle cell patients with 14 leg ulcers lasting from 1 month to 6 years, treated with topical dripping of molgramostim solution.
Results:
Healing was obtained for 9/14 ulcers, with no local or systemic adverse reactions.
Comments:
Molgramostim solution appears to be an adequate therapy for SCD leg ulcers but a more conclusive evaluation will depend on larger series of patients and other types of formulations for topical applications could be even more effective in the future.
